Idera Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (1989)

Organization Overview

First Clinical Trial
2004
NCT00729053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Idera Pharmaceuticals | Idera Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Dermatomyositis (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Kidney Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Melanoma (Phase 3)

Neoplasms (Phase 2)

Psoriasis (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 15